53,626 Shares in Quanterix Co. (NASDAQ:QTRX) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 53,626 shares of the company's stock, valued at approximately $570,000. Raymond James Financial Inc. owned approximately 0.14% of Quanterix as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Invesco Ltd. lifted its holdings in Quanterix by 16.3% in the 4th quarter. Invesco Ltd. now owns 33,654 shares of the company's stock worth $358,000 after buying an additional 4,729 shares during the period. Russell Investments Group Ltd. increased its position in shares of Quanterix by 19.8% during the fourth quarter. Russell Investments Group Ltd. now owns 401,476 shares of the company's stock valued at $4,268,000 after acquiring an additional 66,315 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Quanterix by 22.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 342,264 shares of the company's stock worth $3,638,000 after purchasing an additional 62,757 shares during the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of Quanterix during the fourth quarter valued at approximately $55,000. Finally, Geode Capital Management LLC grew its holdings in shares of Quanterix by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 863,503 shares of the company's stock worth $9,181,000 after acquiring an additional 4,836 shares during the period. Institutional investors own 86.48% of the company's stock.

Quanterix Stock Down 4.2 %

Quanterix stock traded down $0.23 during mid-day trading on Friday, hitting $5.28. The company had a trading volume of 348,159 shares, compared to its average volume of 548,710. Quanterix Co. has a 1 year low of $4.67 and a 1 year high of $19.18. The stock has a market cap of $204.81 million, a price-to-earnings ratio of -4.98 and a beta of 1.12. The business has a fifty day moving average of $6.15 and a 200 day moving average of $9.06.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The business had revenue of $35.16 million for the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Equities analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

QTRX has been the topic of several recent research reports. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Leerink Partnrs cut shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group reduced their target price on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Finally, Leerink Partners restated a "market perform" rating and set a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.20.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.